| Literature DB >> 35324728 |
Masho Hilawie Belay1, Ulrich Precht2,3, Peter Mortensen2, Emilio Marengo1, Elisa Robotti1.
Abstract
The increasing use of pharmaceuticals, their presence in the aquatic environment, and the associated toxic effects, have raised concerns in recent years. In this work, a new multi-residue analytical method was developed and validated for the determination of 10 pharmaceuticals in wastewaters using online solid-phase extraction (online SPE) and liquid chromatography-tandem mass spectrometry (LC-MS/MS). The compounds included in the method were antineoplastics (cabazitaxel, docetaxel, doxorubicin, etoposide, irinotecan, methotrexate, paclitaxel, and topotecan), renin inhibitors (aliskiren), and antidepressants (maprotiline). The method was developed through several experiments on four online SPE cartridges, three reversed phase chromatography columns, and four combinations of mobile phase components. Under optimal conditions, very low limits of detection (LODs) of 1.30 to 10.6 ng L-1 were obtained. The method was repeatable, with relative standard deviations (RSD, %) for intraday and interday precisions ranged from 1.6 to 7.8 and from 3.3 to 13.2, respectively. Recovery values ranged from 78.4 to 111.4%, indicating the reproducibility of the method. Matrix effects were mainly presented as signal suppression, with topotecan and doxorubicin being the two most affected compounds (31.0% signal suppression). The proposed method was successfully applied to hospital effluents, detecting methotrexate (4.7-9.3 ng L-1) and maprotiline (11.2-23.1 ng L-1). Due to the shorter overall run time of 15 min, including sample preparation, and reduced sample volume (0.9 mL), this on-line SPE-LC-MS/MS method was extremely convenient and efficient in comparison to the classical off-line SPE method. The proposed method was also highly sensitive and can be used for ultratrace quantification of the studied pharmaceuticals in wastewaters, providing useful data for effective environmental monitoring.Entities:
Keywords: LC-MS/MS; anticancer drugs; antidepressant; antineoplastic agents; method validation; online SPE; pharmaceuticals; renin inhibitor; wastewater
Year: 2022 PMID: 35324728 PMCID: PMC8955396 DOI: 10.3390/toxics10030103
Source DB: PubMed Journal: Toxics ISSN: 2305-6304
Mobile phase program for the loading and analytical pumps (A = 0.1% (v/v) formic acid in water, B = methanol, C = 0.1% (v/v) formic acid in water, and D = 0.1% (v/v) formic acid in acetonitrile).
| Time | Loading Pump (SPE) | Valve Position | Analytical Pump (HPLC) | |||
|---|---|---|---|---|---|---|
| A (%) | B (%) | Flow Rate (mL min−1) | C (%) | D (%) | ||
| 0.00 | 95.0 | 5.00 | 1.0 | Loading | 95.0 | 5.00 |
| 1.10 | 95.0 | 5.00 | 1.0 | Loading | 95.0 | 5.00 |
| 1.15 | 95.0 | 5.00 | 1.0 | Injection | 95.0 | 5.00 |
| 5.00 | 0.00 | 100 | 0.1 | Injection | 0.00 | 100 |
| 7.00 | 0.00 | 100 | 0.1 | Injection | 0.00 | 100 |
| 8.00 | 0.00 | 100 | 0.1 | Injection | 0.00 | 100 |
| 10.0 | 95.0 | 5.00 | 1.0 | Loading | 95.0 | 5.00 |
| 15.0 | 95.0 | 5.00 | 1.0 | Loading | 95.0 | 5.00 |
Figure 1Configuration of the online SPE and the six-port switching valve.
Molecular formulas and the optimized LC-MS/MS parameters for analyzing the target pharmaceutical compounds. ATZ was used as the internal standard.
| Compound (Abbreviation) | Formula | RT (min) | Precursor Ion, [M + H]+ ( | Product Ions ( | Frag (V) | CE (V) |
|---|---|---|---|---|---|---|
| Aliskiren (ALK) | C30H53N3O6 | 5.0 | 552.4 | 346.3; 534.5 | 135 | 27; 40 |
| Cabazitaxel (CTX) | C45H57NO14 | 7.5 | 836.3 | 555.3; 433.1 | 135 | 20; 20 |
| Docetaxel (DTX) | C43H53NO14 | 6.5 | 808.3 | 527.1; 509.0 | 135 | 20; 15 |
| Doxorubicin (DOX) | C27H29NO11 | 6.1 | 544.0 | 361.2; 397.2 | 135 | 10; 10 |
| Etoposide (ETP) | C29H32O13 | 4.3 | 589.2 | 229.1; 185.2 | 135 | 15; 15 |
| Irinotecan (IRI) | C33H38N4O6 | 1.6 | 587.3 | 124.1; 167.1 | 120 | 45; 21 |
| Maprotiline (MAP) | C20H23N | 5.3 | 278.1 | 250.0; 191.1 | 135 | 15; 15 |
| Methotrexate (MTX) | C20H22N8O5 | 1.4 | 455.2 | 308.1; 175.1 | 120 | 10; 25 |
| Paclitaxel (PTX) | C47H51NO14 | 7.1 | 854.0 | 105.1; 286.0 | 100 | 19; 10 |
| Topotecan (TOP) | C23H23N3O5 | 3.8 | 422.2 | 377.1; 320.0 | 120 | 10; 21 |
| Atrazine-d5 (ATZ) | C8H5H9ClN5 | 5.6 | 221.1 | 179.2; 101.2 | 135 | 20; 20 |
Figure 2Retention differences for paclitaxel and aliskiren by the three analytical columns. PTX by Kinetex (a), Eclipse (b), and Luna Omega (c); ALK by Kinetex (d), Eclipse (e), and Luna Omega (f).
Figure 3Comparison of the recoveries (relative peak area responses) obtained with four online SPE cartridges (analyte concentration 1.0 µg L−1, sample volume 500 µL, n = 3 replicates).
Figure 4Representative chromatogram of the target pharmaceuticals in a mixture of standards (500 ng L−1). The peaks shown are for the quantifier ion transition of each target compound given in Table 2.
Method validation parameters (calibration range, linearity, LOD, LOQ, precision, and recovery). The lowest level of the calibration curve was always the LOQ value. Spiked QC levels for the evaluation of precision and recovery were QCL (LOQ), QCM (100 ng L−1) and QCH (800 ng L−1) for each target compound. RSDs for recoveries shown in parentheses.
| Compound | Linearity (R2) | LOD (ng L−1) | LOQ (ng L−1) | Spiked QC | Precision (RSD %) | Recovery (%) | |
|---|---|---|---|---|---|---|---|
| Intraday | Interday | ||||||
| ALK | 0.9978 | 10.7 | 35.5 | QCL | 5.6 | 13 | 101.6 (5.4) |
| QCM | 3.3 | 9.2 | 95.7 (10) | ||||
| QCH | 3.7 | 7.9 | 94.6 (2.0) | ||||
| CTX | 0.9937 | 7.98 | 26.6 | QCL | 5.5 | 7.0 | 101.3 (2.2) |
| QCM | 6.0 | 4.3 | 94.7 (7.5) | ||||
| QCH | 2.9 | 3.5 | 96.3 (7.1) | ||||
| DTX | 0.9987 | 2.67 | 8.89 | QCL | 7.8 | 11 | 84.0 (11) |
| QCM | 6.7 | 7.9 | 95.3 (8.9) | ||||
| QCH | 8.4 | 6.4 | 96.9 (7.8) | ||||
| DOX | 0.9978 | 2.27 | 7.57 | QCL | 6.1 | 7.5 | 80 (13) |
| QCM | 4.1 | 9.1 | 85.8 (2.9) | ||||
| QCH | 5.5 | 13 | 87.6 (9.1) | ||||
| ETP | 0.9947 | 3.25 | 10.9 | QCL | 3.7 | 9.6 | 104.5 (6.9) |
| QCM | 3.2 | 6.8 | 96.9 (3.8) | ||||
| QCH | 6.2 | 12 | 93.3 (6.8) | ||||
| IRI | 0.9975 | 7.96 | 26.5 | QCL | 4.8 | 9.3 | 78.4 (7.6) |
| QCM | 5.1 | 8.0 | 89.2 (5.4) | ||||
| QCH | 3.9 | 11 | 86.5 (4.4) | ||||
| MAP | 0.9997 | 1.30 | 4.34 | QCL | 2.6 | 8.5 | 103 (14) |
| QCM | 3.3 | 5.4 | 103.2 (6.4) | ||||
| QCH | 2.1 | 5.5 | 98.6 (8.2) | ||||
| MTX | 0.9991 | 4.43 | 14.8 | QCL | 2.1 | 10 | 85.4 (9.0) |
| QCM | 4.4 | 7.7 | 94.4 (5.6) | ||||
| QCH | 3.0 | 5.2 | 111.0 (6.4) | ||||
| PTX | 0.9969 | 6.99 | 23.3 | QCL | 6.6 | 7.8 | 96 (12) |
| QCM | 5.1 | 5.2 | 88.8 (9.2) | ||||
| QCH | 6.7 | 3.3 | 94.6 (7.4) | ||||
| TOP | 0.9982 | 4.22 | 14.1 | QCL | 7.5 | 12 | 92 (11) |
| QCM | 7.4 | 9.4 | 93.7 (9.1) | ||||
| QCH | 6.1 | 9.8 | 96.6 (7.4) | ||||
Figure 5Matrix effects in wastewater influent samples.